Sabine Naudin, Molin Wang, Niki Dimou, Elmira Ebrahimi, Jeanine Genkinger, Hans-Olov Adami, Demetrius Albanes, Ana Babic, Matt Barnett, David Bogumil, Hui Cai, Chu Chen, A Heather Eliassen, Jo L Freudenheim, Gretchen Gierach, Edward L Giovannucci, Marc J Gunter, Niclas Håkansson, Mayo Hirabayashi, Tao Hou, Brian Z Huang, Wen-Yi Huang, Harindra Jayasekara, Michael E Jones, Verena A Katzke, Woon-Puay Koh, James V Lacey, Ylva Trolle Lagerros, Susanna C Larsson, Linda M Liao, Kenneth Lo, Erikka Loftfield, Robert J MacInnis, Satu Männistö, Marjorie L McCullough, Anthony Miller, Roger L Milne, Steven C Moore, Lorelei A Mucci, Marian L Neuhouser, Alpa V Patel, Elizabeth A Platz, Anna Prizment, Kim Robien, Thomas E Rohan, Carlotta Sacerdote, Sven Sandin, Norie Sawada, Minouk Schoemaker, Xiao-Ou Shu, Rashmi Sinha, Linda Snetselaar, Meir J Stampfer, Rachael Stolzenberg-Solomon, Cynthia A Thomson, Anne Tjønneland, Caroline Y Um, Piet A van den Brandt, Kala Visvanathan, Sophia S Wang, Renwei Wang, Elisabete Weiderpass, Stephanie J Weinstein, Emily White, Walter Willett, Alicja Woslk, Brian M Wolpin, Shiaw-Shyuan S Yaun, Chen Yuan, Jian-Min Yuan, Wei Zheng, Paul Brennan, Stephanie A Smith-Warner, Pietro Ferrari
{"title":"Alcohol intake and pancreatic cancer risk: An analysis from 30 prospective studies across Asia, Australia, Europe, and North America.","authors":"Sabine Naudin, Molin Wang, Niki Dimou, Elmira Ebrahimi, Jeanine Genkinger, Hans-Olov Adami, Demetrius Albanes, Ana Babic, Matt Barnett, David Bogumil, Hui Cai, Chu Chen, A Heather Eliassen, Jo L Freudenheim, Gretchen Gierach, Edward L Giovannucci, Marc J Gunter, Niclas Håkansson, Mayo Hirabayashi, Tao Hou, Brian Z Huang, Wen-Yi Huang, Harindra Jayasekara, Michael E Jones, Verena A Katzke, Woon-Puay Koh, James V Lacey, Ylva Trolle Lagerros, Susanna C Larsson, Linda M Liao, Kenneth Lo, Erikka Loftfield, Robert J MacInnis, Satu Männistö, Marjorie L McCullough, Anthony Miller, Roger L Milne, Steven C Moore, Lorelei A Mucci, Marian L Neuhouser, Alpa V Patel, Elizabeth A Platz, Anna Prizment, Kim Robien, Thomas E Rohan, Carlotta Sacerdote, Sven Sandin, Norie Sawada, Minouk Schoemaker, Xiao-Ou Shu, Rashmi Sinha, Linda Snetselaar, Meir J Stampfer, Rachael Stolzenberg-Solomon, Cynthia A Thomson, Anne Tjønneland, Caroline Y Um, Piet A van den Brandt, Kala Visvanathan, Sophia S Wang, Renwei Wang, Elisabete Weiderpass, Stephanie J Weinstein, Emily White, Walter Willett, Alicja Woslk, Brian M Wolpin, Shiaw-Shyuan S Yaun, Chen Yuan, Jian-Min Yuan, Wei Zheng, Paul Brennan, Stephanie A Smith-Warner, Pietro Ferrari","doi":"10.1371/journal.pmed.1004590","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Alcohol is a known carcinogen, yet the evidence for an association with pancreatic cancer risk is considered as limited or inconclusive by international expert panels. We examined the association between alcohol intake and pancreatic cancer risk in a large consortium of prospective studies.</p><p><strong>Methods and findings: </strong>Population-based individual-level data was pooled from 30 cohorts across four continents, including Asia, Australia, Europe, and North America. A total of 2,494,432 participants without cancer at baseline (62% women, 84% European ancestries, 70% alcohol drinkers [alcohol intake ≥ 0.1 g/day], 47% never smokers) were recruited between 1980 and 2013 at the median age of 57 years and 10,067 incident pancreatic cancer cases were recorded. In age- and sex-stratified Cox proportional hazards models adjusted for smoking history, diabetes status, body mass index, height, education, race and ethnicity, and physical activity, pancreatic cancer hazard ratios (HR) and 95% confidence intervals (CI) were estimated for categories of alcohol intake and in continuous for a 10 g/day increase. Potential heterogeneity by sex, smoking status, geographic regions, and type of alcoholic beverage was investigated. Alcohol intake was positively associated with pancreatic cancer risk, with HR30-to-<60 g/day and HR≥60 g/day equal to 1.12 (95% CI [1.03,1.21]) and 1.32 (95% CI [1.18,1.47]), respectively, compared to intake of 0.1 to <5 g/day. A 10 g/day increment of alcohol intake was associated with a 3% increased pancreatic cancer risk overall (HR: 1.03; 95% CI [1.02,1.04]; pvalue < 0.001) and among never smokers (HR: 1.03; 95% CI [1.01,1.06]; pvalue = 0.006), with no evidence of heterogeneity by sex (pheterogeneity = 0.274) or smoking status (pheterogeneity = 0.624). Associations were consistent in Europe-Australia (HR10 g/day = 1.03, 95% CI [1.00,1.05]; pvalue = 0.042) and North America (HR10 g/day = 1.03, 95% CI [1.02,1.05]; pvalue < 0.001), while no association was observed in cohorts from Asia (HR10 g/day = 1.00, 95% CI [0.96,1.03]; pvalue = 0.800; pheterogeneity = 0.003). Positive associations with pancreatic cancer risk were found for alcohol intake from beer (HR10 g/day = 1.02, 95% CI [1.00,1.04]; pvalue = 0.015) and spirits/liquor (HR10 g/day = 1.04, 95% CI [1.03,1.06]; pvalue < 0.001), but not wine (HR10 g/day = 1.00, 95% CI [0.98,1.03]; pvalue = 0.827). The differential associations across geographic regions and types of alcoholic beverages might reflect differences in drinking habits and deserve more investigations.</p><p><strong>Conclusions: </strong>Findings from this large-scale pooled analysis support a modest positive association between alcohol intake and pancreatic cancer risk, irrespective of sex and smoking status. Associations were particularly evident for baseline alcohol intake of at least 15 g/day in women and 30 g/day in men.</p>","PeriodicalId":49008,"journal":{"name":"PLoS Medicine","volume":"22 5","pages":"e1004590"},"PeriodicalIF":15.8000,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12091891/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PLoS Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1371/journal.pmed.1004590","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Alcohol is a known carcinogen, yet the evidence for an association with pancreatic cancer risk is considered as limited or inconclusive by international expert panels. We examined the association between alcohol intake and pancreatic cancer risk in a large consortium of prospective studies.
Methods and findings: Population-based individual-level data was pooled from 30 cohorts across four continents, including Asia, Australia, Europe, and North America. A total of 2,494,432 participants without cancer at baseline (62% women, 84% European ancestries, 70% alcohol drinkers [alcohol intake ≥ 0.1 g/day], 47% never smokers) were recruited between 1980 and 2013 at the median age of 57 years and 10,067 incident pancreatic cancer cases were recorded. In age- and sex-stratified Cox proportional hazards models adjusted for smoking history, diabetes status, body mass index, height, education, race and ethnicity, and physical activity, pancreatic cancer hazard ratios (HR) and 95% confidence intervals (CI) were estimated for categories of alcohol intake and in continuous for a 10 g/day increase. Potential heterogeneity by sex, smoking status, geographic regions, and type of alcoholic beverage was investigated. Alcohol intake was positively associated with pancreatic cancer risk, with HR30-to-<60 g/day and HR≥60 g/day equal to 1.12 (95% CI [1.03,1.21]) and 1.32 (95% CI [1.18,1.47]), respectively, compared to intake of 0.1 to <5 g/day. A 10 g/day increment of alcohol intake was associated with a 3% increased pancreatic cancer risk overall (HR: 1.03; 95% CI [1.02,1.04]; pvalue < 0.001) and among never smokers (HR: 1.03; 95% CI [1.01,1.06]; pvalue = 0.006), with no evidence of heterogeneity by sex (pheterogeneity = 0.274) or smoking status (pheterogeneity = 0.624). Associations were consistent in Europe-Australia (HR10 g/day = 1.03, 95% CI [1.00,1.05]; pvalue = 0.042) and North America (HR10 g/day = 1.03, 95% CI [1.02,1.05]; pvalue < 0.001), while no association was observed in cohorts from Asia (HR10 g/day = 1.00, 95% CI [0.96,1.03]; pvalue = 0.800; pheterogeneity = 0.003). Positive associations with pancreatic cancer risk were found for alcohol intake from beer (HR10 g/day = 1.02, 95% CI [1.00,1.04]; pvalue = 0.015) and spirits/liquor (HR10 g/day = 1.04, 95% CI [1.03,1.06]; pvalue < 0.001), but not wine (HR10 g/day = 1.00, 95% CI [0.98,1.03]; pvalue = 0.827). The differential associations across geographic regions and types of alcoholic beverages might reflect differences in drinking habits and deserve more investigations.
Conclusions: Findings from this large-scale pooled analysis support a modest positive association between alcohol intake and pancreatic cancer risk, irrespective of sex and smoking status. Associations were particularly evident for baseline alcohol intake of at least 15 g/day in women and 30 g/day in men.
期刊介绍:
PLOS Medicine is a prominent platform for discussing and researching global health challenges. The journal covers a wide range of topics, including biomedical, environmental, social, and political factors affecting health. It prioritizes articles that contribute to clinical practice, health policy, or a better understanding of pathophysiology, ultimately aiming to improve health outcomes across different settings.
The journal is unwavering in its commitment to uphold the highest ethical standards in medical publishing. This includes actively managing and disclosing any conflicts of interest related to reporting, reviewing, and publishing. PLOS Medicine promotes transparency in the entire review and publication process. The journal also encourages data sharing and encourages the reuse of published work. Additionally, authors retain copyright for their work, and the publication is made accessible through Open Access with no restrictions on availability and dissemination.
PLOS Medicine takes measures to avoid conflicts of interest associated with advertising drugs and medical devices or engaging in the exclusive sale of reprints.